Tomomi Kogiso1, Hikaru Nagahara2, Motoyuki Otsuka3, Keiko Shiratori4, Steven F Dowdy5. 1. Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. kogiso@ige.twmu.ac.jp. 2. Aoyama Hospital, Tokyo Women's Medical University, 2-7-13 Kita-Aoyama, Minato-ku, Tokyo, 107-0061, Japan. 3. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 4. Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 5. Department of Cellular and Molecular Medicine, UCSD School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093-0686, USA.
Abstract
PURPOSE: Liver transplantation is currently the only curative therapeutic option for end-stage liver cirrhosis. However, due to the limitations of donor liver availability and occasional rejection, it cannot always be successfully applied. In this study, we determined whether fibroblasts can be transdifferentiated into hepatocyte-like cells by transcription factors that initiate and maintain hepatocyte differentiation. METHODS: Fibroblasts were transduced with retrovirus vectors carrying FOXA2, HNF4α, and C/EBPβ. To enhance the efficiency of transdifferentiation, cMyc was also expressed. RESULTS: Transdifferentiation was successful using both neonatal fibroblasts and human forehead fibroblasts. The transdifferentiated cells produced hepatocyte-specific proteins such as albumin and cytochrome, and had important hepatocyte-specific functions, such as glycogen storage and indocyanine green uptake, suggesting that the cells function at least as partial hepatocytes. CONCLUSIONS: These results provide a novel method of generating differentiated hepatocyte-like cells, and may represent an alternative source of cells for future cell-based therapeutics for end-stage liver diseases.
PURPOSE: Liver transplantation is currently the only curative therapeutic option for end-stage liver cirrhosis. However, due to the limitations of donor liver availability and occasional rejection, it cannot always be successfully applied. In this study, we determined whether fibroblasts can be transdifferentiated into hepatocyte-like cells by transcription factors that initiate and maintain hepatocyte differentiation. METHODS: Fibroblasts were transduced with retrovirus vectors carrying FOXA2, HNF4α, and C/EBPβ. To enhance the efficiency of transdifferentiation, cMyc was also expressed. RESULTS: Transdifferentiation was successful using both neonatal fibroblasts and human forehead fibroblasts. The transdifferentiated cells produced hepatocyte-specific proteins such as albumin and cytochrome, and had important hepatocyte-specific functions, such as glycogen storage and indocyanine green uptake, suggesting that the cells function at least as partial hepatocytes. CONCLUSIONS: These results provide a novel method of generating differentiated hepatocyte-like cells, and may represent an alternative source of cells for future cell-based therapeutics for end-stage liver diseases.
Authors: Andrea Jochheim; Tina Hillemann; Gabriela Kania; Jennifer Scharf; Masoumeh Attaran; Michael P Manns; Anna M Wobus; Michael Ott Journal: Int J Dev Biol Date: 2004-02 Impact factor: 2.203
Authors: H Aurich; M Sgodda; P Kaltwasser; M Vetter; A Weise; T Liehr; M Brulport; J G Hengstler; M M Dollinger; W E Fleig; B Christ Journal: Gut Date: 2008-11-20 Impact factor: 23.059
Authors: Fereshteh Parviz; Christine Matullo; Wendy D Garrison; Laura Savatski; John W Adamson; Gang Ning; Klaus H Kaestner; Jennifer M Rossi; Kenneth S Zaret; Stephen A Duncan Journal: Nat Genet Date: 2003-07 Impact factor: 38.330
Authors: Owen J L Rackham; Jaber Firas; Hai Fang; Matt E Oates; Melissa L Holmes; Anja S Knaupp; Harukazu Suzuki; Christian M Nefzger; Carsten O Daub; Jay W Shin; Enrico Petretto; Alistair R R Forrest; Yoshihide Hayashizaki; Jose M Polo; Julian Gough Journal: Nat Genet Date: 2016-01-18 Impact factor: 38.330